Affordable Access

deepdyve-link
Publisher Website

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.

Authors
  • Girard, P M1
  • Antinori, A2
  • Arribas, J R3
  • Ripamonti, D4
  • Bicer, C5
  • Netzle-Sveine, B6
  • Hadacek, B6
  • Moecklinghoff, C7
  • 1 Department of Infectious and Tropical Diseases, Hôpital Saint-Antoine, AP-HP, INSERM UMR S 1136, Paris, France. , (France)
  • 2 National Institute for Infectious Diseases, L. Spallanzani IRCCS, Rome, Italy. , (Italy)
  • 3 Hospital University La Paz, IdiPAZ, Madrid, Spain. , (Spain)
  • 4 University Hospital, Bergamo, Italy. , (Italy)
  • 5 Biostatistics, Janssen R&D, Beerse, Belgium. , (Belgium)
  • 6 Janssen EMEA, Issy-les-Moulineaux, France. , (France)
  • 7 Janssen EMEA, Neuss, Germany. , (Germany)
Type
Published Article
Journal
HIV medicine
Publication Date
Jan 01, 2017
Volume
18
Issue
1
Pages
5–12
Identifiers
DOI: 10.1111/hiv.12386
PMID: 27279571
Source
Medline
Keywords
License
Unknown

Abstract

In this study, in patients with HIV-1 RNA < 50 copies/mL at baseline, switching to DRV/r monotherapy showed lower efficacy vs. triple therapy at week 96 in the primary ITT switch-equals-failure analysis, particularly in patients with CD4 counts < 200 cells/μL.

Report this publication

Statistics

Seen <100 times